Heterogeneity of carboxyl-terminal parathyroid hormone circulating forms in patients with hyperparathyroidism due to end stage renal disease;Heterogeneidade das formas carboxi-terminal circulantes de paratormônio em pacientes com hiperparatiroidismo devido à insuficiência renal crônica terminal

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 9, 2009, Pages 1074-1078

  Vieira, José Gilberto H ^a   Kunii, Ilda S ^a   Ohe, Monique N ^a   Carvalho, Aluizio B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carboxyl terminal fragments of PTH; Chromatography; End stage kidney disease; Gel; PTH assays

Indexed keywords

EID: 77149148112     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302009000900003     Document Type: Article

References (23)

1. Loveridge N, Dean V, Goltzman D, Hendy GN. Bioactivity of parathyroid hormone and parathyroid hormone-like peptide: agonist and antagonist activities of amino-terminal fragments as assessed by the cytochemical bioassay and in situ biochemistry. Endocrinology. 1991;128(4):1938-46.
2. Berson AS, Yaloow RS, Aurbach GD, Potts JT. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci USA. 1963;49(5):613-6.
3. Vieira JGH, Kunii IS, Nishida SK. Evolution of PTH assays. Arq Bras Endocrinol Metabol. 2006;50(4):621-7.
4. Nussbaum SR, Zaharadnik RJ, Lavigne JR, Brennan GL, NozawaUng K, Kim L, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33(8):1364-7.
5. Quarles LD, Lobauch B, Murphy G. Intact parathyroid hormone over-estimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab. 1992;75(1):143-50.
6. Brandão CM, Kasamatsu TS, Oliveira MA, Vieira JG. Circulating molecular forms of parathyroid hormone in primary and secondary hyperparathyroidism. Braz J Med Biol Res. 1989;22(8):963-5.
7. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81(11):3923-9.
8. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60(4):1460-8.
9. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40(2):348-54.
10. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RL, Gales B, et al. Similar predictive value of bone turnover using first- and second generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63(5):1801-8.
11. Divieti P, Inomata N, Chapin K, Singh R, Jüppner H, Bringhurst FR. Receptors for the carboxyl-terminal region of PTH (1-84) are highly expressed in osteocitic cells. Endocrinology. 2001;142(2):916-25.
12. Divieti P, Geller AI, Suliman G, Jüppner H, Bringhurst FR. Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology. 2005;146(4):1863-70.
13. Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for carboxyl-terminal region and related biological actions of carboxylterminal ligands. Endocr Rev. 2005;26(1):78-113.
14. Vieira JG, Nishida SK, Kasamatsu TS, Amarante EC, Kunii IS. Development and clinical application of an immunofluorometric assay for intact parathyroid hormone. Braz J Med Biol Res. 1994;27(10):2379-82.
15. Vieira JG, Nishida SK, Camargo MT, Obara LH, Kunii IS, Ohe MN, et al. [Parathyroid hormone values obtained with immunometric assays depend on the amino-terminal antibody specificity]. Arq Bras Endocrinol Metab. 2004;48(4):518-24.
16. de Deuxchaisnes CN, Fisher JA, Dambacher MA, Devogelaer JP, Arber CE, Zanelli JM, et al. Dissociation of parathyroid hormone bioactivity in pseudohypoparathyroidism type I. J Clin Endocrinol Metab. 1981;53:1105-9.
17. Murray TM, Rao LG, Muzaffar SA. Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide hPTH (53-84): stimulation of alkaline phosphatase. Calcif Tissue Int. 1991;49(2):120-3.
18. Banerjee S, Selim H, Suliman G, Geller AI, Jüppner H, Bringhurst FR, et al. Synthesis and characterization of novel biotinylated carboxyl-terminal parathyroid hormone peptides that specifically crosslink to CPTH-receptor. Peptides. 2006;27(12):3352-62.
19. Selim AA, Mahon M, Juppner H, Bringhurst FR, Divieti P. Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling. Am J Physiol Cell Physiol. 2006;291(1):C114-21.
20. Kunii IS, Vieira JGH. Circulating forms of parathyroid hormone detected with an immunofluorometric assay in patients with primary hyperparathyroidism and in hyperparathyroidism secondary to chronic renal failure. Braz J Med Biol Res. 2001;34(12):1547-50.
21. Brossard JH, Yamamoto LN, D'Amour P. Parathyroid hormone metabolites in renal failure: bioactivity and clinical implications. Seminars in Dialysis. 2002;15(3):196-201.
22. Friedman PA, Goodman WG. PTH(1-84)/PTH(7-84): a balance of power. Am J Physiol Renal Physiol. 2006;290(5):F975-84.
23. Zhang C-X, Weber BV, Thammavong J, Grover TA, Wells DS. Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem. 2006;78(5):1636-43.